NCT00349466View on ClinicalTrials.gov

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

PHASE2CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG

CF101

Orally CF101 1mg

DRUG

Placebo

Orally matching Placebo

Trial Locations (3)

5262

Sheba Medical Center, Tel Litwinsky

44281

Meir Hospital, Kfar Saba

70300

Assaf Harofeh Medical Center, Ẕerifin

Sponsors

Lead Sponsor

Can-Fite BioPharma

All Listed Sponsors

lead

Can-Fite BioPharma

INDUSTRY